Trial Search Results

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Adicet Bio, Inc

Stanford Investigator(s):


  • Genetic: ADI-001


Inclusion Criteria:

   - All patients who received any Adicet allogeneic CAR T investigational product and have
   either completed the core treatment protocol or have discontinued early

   - All patients who are willing and able to adhere to the study visit schedule and other
   protocol requirements.

   - Capable of giving signed informed consent which includes compliance with requirements
   and restrictions listed in the informed consent form (ICF) and protocol

Exclusion Criteria:

   - There are no specific exclusion criteria for this study

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David Miklos, MD
Not Recruiting